IN2014MN01486A - - Google Patents

Info

Publication number
IN2014MN01486A
IN2014MN01486A IN1486MUN2014A IN2014MN01486A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A IN 1486MUN2014 A IN1486MUN2014 A IN 1486MUN2014A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A
Authority
IN
India
Prior art keywords
hcv
inhibitors
solvates
meaning
preparing
Prior art date
Application number
Other languages
English (en)
Inventor
Koen Vandyck
Pierre Jean Marie Bernard Raboisson
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of IN2014MN01486A publication Critical patent/IN2014MN01486A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
IN1486MUN2014 2011-12-28 2012-12-27 IN2014MN01486A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195841 2011-12-28
EP12152267 2012-01-24
PCT/EP2012/076942 WO2013098320A1 (en) 2011-12-28 2012-12-27 Quinazolinone derivatives as hcv inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN01486A true IN2014MN01486A (enExample) 2015-04-24

Family

ID=47505013

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1486MUN2014 IN2014MN01486A (enExample) 2011-12-28 2012-12-27

Country Status (12)

Country Link
US (1) US9382261B2 (enExample)
EP (1) EP2797913B1 (enExample)
JP (2) JP6199891B2 (enExample)
CN (1) CN104169271B (enExample)
AU (1) AU2012360910B8 (enExample)
BR (1) BR112014016007A8 (enExample)
CA (1) CA2858646A1 (enExample)
ES (1) ES2601461T3 (enExample)
IN (1) IN2014MN01486A (enExample)
MX (1) MX348127B (enExample)
RU (1) RU2014131017A (enExample)
WO (1) WO2013098320A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2680507A1 (en) 2006-10-13 2008-04-24 Xtl Biopharmaceuticals Ltd. Compounds and methods for treatment of hcv
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AU2009322393B2 (en) * 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2011004276A1 (en) * 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2011109037A1 (en) * 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
AU2011284857B2 (en) * 2010-07-26 2014-07-24 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
MX340033B (es) * 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.

Also Published As

Publication number Publication date
ES2601461T3 (es) 2017-02-15
MX2014008042A (es) 2014-08-21
EP2797913A1 (en) 2014-11-05
JP6199891B2 (ja) 2017-09-20
CN104169271B (zh) 2017-04-05
JP2015503537A (ja) 2015-02-02
EP2797913B1 (en) 2016-08-17
BR112014016007A2 (pt) 2017-06-13
WO2013098320A1 (en) 2013-07-04
CA2858646A1 (en) 2013-07-04
AU2012360910A8 (en) 2017-02-02
MX348127B (es) 2017-05-26
RU2014131017A (ru) 2016-02-20
US20140378485A1 (en) 2014-12-25
BR112014016007A8 (pt) 2017-07-04
US9382261B2 (en) 2016-07-05
JP2018012699A (ja) 2018-01-25
AU2012360910B2 (en) 2017-01-05
CN104169271A (zh) 2014-11-26
AU2012360910B8 (en) 2017-02-02
AU2012360910A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
PH12019502355A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
PH12018501812A1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
PH12016500027B1 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
IN2014MN01465A (enExample)
PH12016500723B1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX366787B (es) Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
PH12015500780A1 (en) Rsv antiviral compounds
MX353412B (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
UA115069C2 (uk) Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
IN2013MU01247A (enExample)